Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of abiraterone acetate plus prednisone versus placebo plus prednisone after docetaxel failure in metastatic castration-resistant prostate cancer
NL-OMON32133Phase 3Not yet recruiting
- Sponsor
- Cougar Biotechnology
- Start
- Jun 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Abiraterone acetate plus prednisone with Placebo plus prednisone (2 arms). Primary endpoint: Overall survival. Planned start Jun 2008; status: not yet recruiting.
02
Drugs
abirateroneprednisone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON32133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32133.